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Summary
Squamous cell carcinoma of uterine cervix is potentially 
a curable disease; however, many patients treated with 
definitive chemoradiotherapy develop distant metastases, 
with few of them having a single metastatic deposit. 
There are no guidelines for the treatment of patients with 
oligometastatic cervical cancer.
We present a case of a patient with International 
Federation of Gynecology and Obstetrics (FIGO) Stage 
IIB squamous cell carcinoma of uterine cervix. She was 
successfully treated with concurrent chemoradiotherapy 
with definitive intent. One year later, she developed a 
solitary pulmonary nodule for which she underwent 
resection followed by chemotherapy. She is free of any 
local or distant disease at 5 years of regular follow-up.
Background
Cervical cancer is the fourth most common malig-
nancy among women in developing countries and 
majority of them are diagnosed in advanced stage, 
beyond surgical treatment.1 There has been a consid-
erable improvement in long-term survival of patients 
with locally advanced cervical cancer.2 3 However, 
still there is a large proportion of patients who 
develop distant metastases, and few of them present 
with an oligometastatic disease. There are no guide-
lines for such patients. If treated aggressively, a small 
proportion of patients can still be cured. We present 
a case of a woman, who completed treatment with 
chemoradiotherapy and later on developed a solitary 
right lung base metastasis.
caSe preSentation
A 54-year-old woman, known asthmatic, mother 
of 3 children, presented with postmenopausal 
vaginal bleeding in July 2010. There was no 
fever, itching or any history of contraceptive 
or antibiotic use. She had insignificant family 
history. Vaginal examination showed a barrel-
shaped cervix, vaginal fornices were obliterated 
and shallow and a nodule was palpable in the left 
parametrium.
Considering the clinical findings, it was planned 
to examine the patient under anaesthesia (EUA). On 
EUA, a friable growth coming out of cervix was seen, 
a hysteroscope was introduced simultaneously which 
revealed cervix and uterus filled with growth. Curet-
tage was performed and friable pieces of growth were 
obtained and sent for histopathology.
Sections from endocervical curettings revealed a 
tumour composed of sheets and groups of squamous 
epithelial cells, having large round to oval nuclei 
with prominent nucleoli showing pleomorphism 
and hyperchromasia. The cytoplasm was eosino-
philic, forming intercellular bridges. Tumour was 
infiltrating into the muscle tissue. Scattered chronic 
inflammatory cells were seen. On immunohisto-
chemical staining, the tumour cells show positivity 
for cytokeratin 5/6 and p16 (figure 1A,B).
Metastatic workup was negative for any distant 
disease. She was staged as International Federation 
of Gynecology and Obstetrics (FIGO) IIB, grade 
III squamous cell carcinoma cervix for which she 
was treated with pelvic radiotherapy and concur-
rent cisplatin chemotherapy (40 mg/m2). Pelvic 
radiation consisted of a dose of 45 Gy in 25 frac-
tions via external beam radiation therapy followed 
by 3 sessions of high-dose rate intracavitary 
brachytherapy. At the end of treatment, the cervical 
mass had disappeared. On her first post-treat-
ment follow-up in December 2010, there was no 
evidence of local disease on clinical examination, 
and CT scan of chest, abdomen and pelvis was also 
negative for any locoregional or distant disease.
She was on regular follow-up and in June 2011 
on routine follow-up CT scan of chest, abdomen 
and pelvis, there was a 3×3 cm nodule in right 
lung base (figure 2). The case was discussed in 
multidisciplinary team meeting and recommended 
to undergo right lower lobectomy for solitary lung 
lesion. Histopathology was consistent with poorly 
differentiated metastatic carcinoma (figure 3A,B). 
After surgery, she was given six cycles of carbo-
platin (area under curve (AUC) 6) and paclitaxel 
(175 mg/m2) chemotherapy, which she completed 
in November 2011.
outcome and follow-up
The patient visited the clinics regularly where 
local examination was done every 3 months along 
with an annual CT chest, abdomen and pelvis. 
After 5 years of surveillance, she is free of any 
disease on examination and on imaging.
diScuSSion
Pulmonary metastasectomy is a recognised therapeutic 
modality for the treatment of metastatic disease. 
Surgical resections have been widely performed on 
patients with pulmonary metastasis from soft tissue 
sarcoma and colorectal cancer. However, the role of 
metastasectomy in metastatic squamous cell carcinoma 
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of uterine cervix is not well explored. There are currently no stan-
dard surgical options for pulmonary metastasis.
Okiror et al showed that pulmonary metastasectomy confers 
an improved survival in patients with metastatic sarcoma. A 
total of 80 pulmonary metastasectomies were performed on 
66 patients. The median number of metastases resected was 
three, and there were no postoperative in-hospital deaths. The 
median overall survival (OS) was 25.5 months; however, recur-
rence of metastases significantly affected survival.4
Historically, the clinical practices with respect to colorectal 
cancers have been reviewed thoroughly focusing on the detection 
of lung and liver metastasis and their subsequent resections.5 In a 
retrospective study, Hattori et al evaluated outcomes after pulmo-
nary resection of colorectal metastases in patients with or without a 
curative hepatic metastasectomy. The 5-year OS of the lung metasta-
sectomy group was significantly better than that of the liver and lung 
metastasectomy group.6 Similarly, a Japanese study showed that 
surgical resection offers a chance to prolong survival in colorectal 
cancer patients with resectable pulmonary metastases.7
Apart from sarcomas and adenocarcinomas, the role of metas-
tasectomy in metastatic squamous cell carcinoma is not well 
established. A systematic review of studies examining outcomes 
for patients with head and neck squamous cell carcinoma who 
underwent pulmonary metastasectomy for metachronous pulmo-
nary metastases was conducted in the UK, but it only provided 
limited evidence in the favour of pulmonary metastasectomy.8
Little is known about the long-term survival after pulmonary 
metastasectomy for gynaecological malignancies. Tumour histo-
pathology, duration of disease-free interval after the treatment 
of primary site, number of pulmonary metastases and absence 
of extra pulmonary disease have been identified as indepen-
dent prognostic factors in the management of metastatic gynae-
cological malignancies.9 10 There are few single institutional 
reports highlighting this subject. Adachi et al reported a 5-year 
OS of 81.7% in 37 patients with isolated lung metastases (<3 
nodules). The histopathology of gynaecological tumours was not 
mentioned in this study.11
A retrospective analysis of 103 patients conducted at Mayo 
Clinic showed that pulmonary resection for metastatic gynaecolog-
ical cancer in selected patients is safe and effective. However, the 
majority of the patients had disease in uterine corpus, while cervix 
was involved in only seven. Furthermore, merely five patients had 
disease with squamous cell histology.12 A study by Anraku et al 
stratified the 5-year OS for each histological type. Squamous cell 
carcinomas of cervix had better 5-year OS when compared with 
cervical adenocarcinomas. The same study showed that patients 
with a disease-free interval of 12 months or more are good candi-
dates for metastasectomy, provided there is adequate control of the 
primary tumour without extra pulmonary metastasis.9
Our patient was found to have a solitary metastatic nodule in 
lung on routine follow-up and systemic investigations. Considering 
her good performance status, she was offered metastasectomy. 
Anticipating the presence of microscopic disease elsewhere based 
on biopsy-proven metastasis in lung, she was given postoperative 
chemotherapy consisting of carboplatin at a dose of AUC 6 and 
paclitaxel at doses of 175 mg/m2 every three weeks. She toler-
ated this treatment uneventfully and is disease free after 5 years of 
treatment. However, there is no data in the contemporary litera-
ture emphasising the significance of adjuvant chemotherapy after 
metastasectomy.
The largest report to date, a multi-institutional study including 
cervical cancer patients exclusively, reported a 5-year disease-free 
survival (DFS) rate of 32.9% after pulmonary metastasectomy. 
Patients with one or two pulmonary metastases had a 5-year DFS 
rate of 42.2% compared with 0% for patients with three or four 
metastases. Patients with squamous cell cancers had a 5-year DFS 
rate of 47.4%, compared with 0% for patients with adenosqua-
mous cell cancers or adenocarcinoma.10
These existing reports on the role of metastasectomy in 
cases of squamous cell carcinoma of cervix with oligometa-
static disease emphasise the need for an aggressive treatment 
approach, considering it as potentially a curative treatment. 
However, there is a swift need for multicenter collaboration that 
will establish the clinical guidelines for the better management 
of such patients.
figure 1 (A) H&E staining shows an infiltrating tumour arranged in 
nests with overlying endocervical columnar lining (B) Tumour cells are 
positive for p16 immunohistochemical stain.
figure 2 Axial CT scan showing right lung base nodule.
figure 3 (A) Metastatic squamous cell carcinoma to lung filling the 
alveoli. (B) Tumour cells showing nuclear positivity for p16 immunostain.
learning points
 ► International Federation of Gynecology and Obstetrics (FIGO) 
stage IV B squamous cell carcinoma of uterine cervix with 
solitary metastasis can be approached aggressively with a 
curative intent.
 ► Like established therapeutic roles in sarcomas and colorectal 
cancer, local treatment of distant metastasis has a probable 
role in the management of carcinoma of cervix.
 ► Multidisciplinary team care is the key to success.
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